because NYR is an American company, I believe a nasdaq listing before phase 2 will be on the cards. Will put it well north of a 100 million market cap. AGN my prediction based off 3 decades of information on glutamate antagonist for stroke will fail like the others before it because glutamate is needed for neuron survival in TBI and stroke after 30 mins of injury
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.18M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.0¢ | $114.5K | 576.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 78460 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 60000 | 2 |
View Market Depth
| Last trade - 15.59pm 16/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |